Compounded Tirzepatide: Which Pharmacies Still Offer It Legally in 2026?
The FDA removed tirzepatide from the shortage list in December 2024. More than a year later, compounded versions are still available — but the legal basis has shifted. Here's what you need to know.
Tirzepatide (brand names Mounjaro and Zepbound) became the most sought-after weight loss medication in 2024. Its dual GLP-1/GIP mechanism showed superior weight loss compared to semaglutide in head-to-head trials — up to 22.5% body weight reduction in the SURMOUNT trials. Demand vastly exceeded supply, and compounding pharmacies filled the gap.
Then the shortage ended. The FDA removed tirzepatide from the shortage list in December 2024, with compounders expected to wind down production by March 2025. But compounded tirzepatide didn't disappear. Understanding why — and which providers are operating on solid legal ground — matters for anyone considering this medication today.
The Two Legal Pathways for Compounded Tirzepatide
The most common approach. Compounders create formulations that differ meaningfully from branded Mounjaro/Zepbound — different concentrations, added ingredients (B12, L-carnitine), alternative delivery methods (sublingual, troche). Under the FD&C Act, these formulations can be compounded without a shortage designation because they're not "essentially copies" of the commercial product.
Traditional 503A compounding pharmacies can prepare patient-specific prescriptions when a prescriber determines an individual patient needs a customized medication. This pathway doesn't depend on shortage status at all — it's been the foundation of compounding pharmacy law for decades. However, it requires a genuine patient-specific prescription and cannot support mass production.
Producing compounded tirzepatide that is "essentially a copy" of Mounjaro or Zepbound — same formulation, same concentration, no meaningful difference — without a shortage designation. Providers operating this way are at risk of FDA enforcement action. Eli Lilly has also pursued aggressive trademark litigation against compounders using the Mounjaro or Zepbound brand names.
How to Tell If a Provider Is Operating Legally
Ask these specific questions before choosing a compounded tirzepatide provider:
What makes your formulation different from branded Zepbound? A legitimate answer references specific formulation differences — added ingredients, different concentration, alternative delivery method. A red flag is vagueness or claiming their product is "the same as Zepbound."
Is your compounding pharmacy 503A or 503B? Both can legally compound tirzepatide under appropriate conditions, but the answer tells you about the oversight structure. 503B facilities are FDA-registered and follow current Good Manufacturing Practice standards.
Does your pharmacy perform third-party potency testing? This isn't legally required for 503A pharmacies but is a strong quality signal. 503B facilities should have this as standard practice. The FDA's own testing found potency variations of 42% to 170% in compounded GLP-1 products — testing is critical.
Has your company received any FDA warning letters? Warning letters are public record and searchable on the FDA's website. A provider with an unresolved warning letter related to compounded GLP-1 products warrants extra scrutiny.
Current Pricing for Compounded Tirzepatide
Compounded tirzepatide generally costs more than compounded semaglutide due to higher API (active pharmaceutical ingredient) costs. Most providers price it between $199 and $350 per month, compared to $146–$299 for semaglutide. The brand-name alternative — Zepbound through LillyDirect — is available at $399/month for self-pay patients.
The narrowing price gap between compounded and brand-name tirzepatide is worth considering. At the high end of compounded pricing ($300–$350), you're paying within $50–$100/month of FDA-approved Zepbound. The value proposition for compounded tirzepatide is strongest at lower price points.
Providers Offering Compounded Tirzepatide in 2026
SHED
Compounded semaglutide + tirzepatide · From $297/mo · 503B pharmacy partner
Yucca Health
Compounded tirzepatide from $258/mo (6-mo plan) · Semaglutide from $146/mo
Should You Choose Compounded Tirzepatide or Brand-Name Zepbound?
There's no universal right answer. Compounded tirzepatide offers lower cost and formulation flexibility. Brand-name Zepbound offers FDA approval, standardized manufacturing, and the auto-injector pen (vs. vial-and-syringe for most compounded products). At $399/month through LillyDirect, Zepbound is within reach for many patients who were previously priced out.
The deciding factors are usually budget, comfort with compounding, and how important FDA oversight is to you personally. Both options deliver tirzepatide — the clinical outcomes depend on consistent dosing and adherence, regardless of source.
Compare All Tirzepatide Providers
Brand-name and compounded options, side by side.
Compare Providers →Sources
- FDA — Tirzepatide shortage resolution notice, December 2024
- FDA — Compounding and the FDA: Questions and Answers (503A and 503B frameworks)
- SURMOUNT clinical trial program — tirzepatide weight loss data (Eli Lilly)
- FDA — Warning letters to compounding pharmacies, September 2025 batch
- Eli Lilly — LillyDirect self-pay pricing for Zepbound, accessed May 2026
- FDA — Compounded Drug Products That Are Essentially a Copy of a Commercially Available Drug Product (Guidance for Industry)